Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?

Bennett, Charles L.; Matchar, David B.; McCrory, Doug; McLeod, David G.; Crawford, E. David; Hillner, Bruce E.

doi:10.1002/(sici)1097-0142(19960501)77:9<1854::aid-cncr15>3.3.co;2-0

Cited by 9 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two of the nine papers reported some of the same result. 140,141 The abstract by Cowen 142 reported a pilot study, which led to a more comprehensive piece of work reported later by the same author. 143 This left eight separate studies of prostate cancer utilities to be considered.…”

Section: Adverse Effects Of Treatmentmentioning

confidence: 99%

“…For this reason studies that implicitly, or explicitly, assume that men of the age being considered are in perfect health (or that ideal health for that age group is the relevant comparator) are likely to result in higher utility values than those that do not. Of the eight utility studies three state that a utility of 1 is defined as perfect health: Cowen, 143 Bennett 140,141 and Souchek. 148 The Q-tility instrument used by Rosendahl 147 is not described and it is therefore not clear how a utility of 1 is defined.…”

Section: Definition Of 'Perfect Health' or Utility Ofmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

107

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. HTAISSN 1366-5278 © Queen's Printer and Controller of HMSO 2003This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.Applications for commercial reproduction should be addressed to HMSO,The Copyright Unit, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ.Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

Section: Adverse Effects Of Treatmentmentioning

confidence: 99%

Section: Definition Of 'Perfect Health' or Utility Ofmentioning

confidence: 99%

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

107

View full text Add to dashboard Cite

show abstract

“…The utility for the last year of life while patients were receiving chemotherapy and other supportive therapy was obtained from the literature and was estimated at 0.42. 14 Distributions were sampled for each utility at random from the treatment utilities by using a secondorder Monte-Carlo simulation technique. Utilities were modeled using a ␤ distribution.…”

Section: Utilitiesmentioning

confidence: 69%

Long‐term hormone therapy and radiation is cost‐effective for patients with locally advanced prostate carcinoma

Konski

Bruner

Brereton

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDIn Radiation Therapy Oncology Group (RTOG) trial 92‐02, after men received neoadjuvant hormone cytoreduction and radiotherapy for locally advanced prostate carcinoma, they were randomized to receive either 2 years of long‐term androgen‐deprivation (LTAD) or no further treatment (short‐term androgen‐deprivation [STAD]). The specific objective of the current study was to determine whether LTAD was a cost‐effective treatment for patients with locally advanced prostate carcinoma.METHODSThe cost‐effectiveness of LTAD was tested using a Markov model that was designed using proprietary software. The analysis took a payor's perspective. Unit costs were obtained by estimation using a global Medicare fee schedule. Costs and outcomes were discounted by 3%. Distributions were sampled at random from the treatment utilities, transition probabilities, and costs using a second‐order Monte Carlo simulation technique.RESULTSThe expected mean cost was $32,564 for LTAD compared with $33,039 for STAD after accounting for the additional cost of salvage treatment for men who were treated with STAD. The mean number of quality‐adjusted life years (QALYs) for men who received LTAD was 4.13 QALYs compared with a mean of 3.68 QALYs for men who received STAD. The cost‐effectiveness acceptability curve analysis showed a 91% probability that LTAD was cost‐effective compared with STAD. Although overall survival was similar in the LTAD and STAD groups, the patients who received LTAD experienced gains in QALYs and had lower costs, because LTAD prevented biochemical failure and the necessitating salvage hormone therapy.CONCLUSIONSThe current analysis showed that LTAD was cost‐effective for the entire population studied in RTOG trial 92‐02. Cancer 2006. © 2005 American Cancer Society.

show abstract

“…17 For men who accept it, orchiectomy is likely to be the most cost-effective androgen suppression strategy. Combined androgen blockade is the least economically attractive option, yielding small health benefits at relatively high costs Bloomfield et al, 1998 10 The use of mitoxantrone and prednisone does not incur in any additional cost over the use of prednisone alone, due to its best effectiveness require fewer hospital admissions Bennett et al 1996 11 Total androgen blockade improves survival and has maximal benefit in minimal disease patients. Although Hillner, 1996 12 orchiectomy is cheaper than LhRH treatment, total androgen blockade has an incremental costHillner et al, 1995 Economic assessment studies that compare different treatment alternatives available based on high quality evidence are highly recommended.…”

Section: Discussionmentioning

confidence: 99%

Could we measure the efficiency of prostate cancer treatment? A critical appraisal of economic evaluation studies

García-Altés

Aj²

2001

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this paper is to introduce the methodology of economic analysis in health care, and its application to the measurement of the efficiency analysis of prostate cancer treatment. We presented the methodology of economic analysis. To review its application in prostate cancer treatment, we performed a bibliographic search in the main biomedical databases (February 1988 -January 2001 to identify economic evaluation studies that compared both costs and effects of prostate cancer treatments. The lack of economic studies for localized prostate cancer and the diversity of treatments for advanced prostate cancer make it difficult to make comparisons across studies and to make therapeutic recommendations. Prostate Cancer and Prostatic Diseases (2001) 4, 217-220.

show abstract

Cost‐effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?

Cited by 9 publications

References 0 publications

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Long‐term hormone therapy and radiation is cost‐effective for patients with locally advanced prostate carcinoma

Could we measure the efficiency of prostate cancer treatment? A critical appraisal of economic evaluation studies

Contact Info

Product

Resources

About